Combinational therapy for synergistic inhibition of gram-positive and gram-negative bacteria

Patent metadata

Field	Value
Publication number	US-10420815-B2
Application number	US-201615760061-A
Country	US
Kind code	B2
Filing date	Sep 15, 2016
Priority date	Sep 15, 2015
Publication date	Sep 24, 2019
Grant date	Sep 24, 2019

Abstract

Compositions and methods for inhibiting the growth of Gram-negative and/or Gram-positive bacteria and pharmaceutical compositions for treating infections of such bacteria in humans and animals are provided. An exemplary method for inhibiting the growth of Gram-negative and/or Gram-positive bacteria includes contacting the bacteria or an environment containing the bacteria with a combination of bacitracin and a gallate ester. An exemplary pharmaceutical composition includes bacitracin and a gallate ester.

First claim

We claim:

1. A method for inhibiting the growth of Gram-negative and/or Gram-positive bacteria which comprises contacting the bacteria or an environment containing the bacteria with a combination of bacitracin and a gallate ester, wherein the gallate ester is octyl gallate, lauryl gallate or an aryl gallate ester.

2. The method of claim 1 , wherein the gallate ester is octyl gallate or lauryl gallate.

3. The method of claim 1 , wherein the gallate ester is an aryl gallate ester.

4. The method of claim 1 , wherein the weight ratio of bacitracin to gallate ester is less than 0.1.

5. The method of claim 1 , wherein the bacteria are Gram-positive bacteria.

6. The method of claim 1 , wherein the bacteria are Staphylococcus aureus.

7. The method of claim 1 , wherein the bacteria are methicillin-resistant Staphylococcus aureus.

8. A method for inhibiting the growth of Gram-negative bacteria which comprises contacting the bacteria or an environment containing the bacteria with a combination of bacitracin and a gallate ester.

9. The method of claim 8 , wherein the bacteria are bacitracin-resistant Gram-negative bacteria.

10. The method of claim 8 , wherein the Gram-negative bacteria are E. coli or Salmonella strains.

11. A method of treating a bacterial infection in an individual in need of such treatment which comprises administering to the individual a combined effective amount of bacitracin and a gallate ester, wherein the gallate ester is octyl gallate, lauryl gallate or an aryl gallate ester.

12. The method of claim 11 , wherein the gallate ester is octyl gallate or lauryl gallate.

13. The method of claim 11 , wherein the weight ratio of bacitracin to gallate ester ranges from 0.1 to 0.0001.

14. The method of claim 11 , wherein the bacteria are Gram-positive bacteria.

15. The method of claim 11 , wherein a wound is treated by applying the combination of bacitracin and the gallate ester to the wound.

16. The method of claim 11 , wherein the gallate ester is an aryl gallate ester.

17. A method of treating a bacterial infection in an individual in need of such treatment which comprises administering to the individual a combined effective amount of bacitracin and a gallate ester, wherein the infection is a Gram-negative bacterial infection.

18. A pharmaceutical composition which comprises bacitracin and a gallate ester, wherein the gallate ester is octyl gallate, lauryl gallate or an aryl gallate ester.

19. The pharmaceutical composition of claim 18 , wherein the gallate ester is octyl gallate or lauryl gallate.

20. The pharmaceutical composition of claim 18 , wherein the gallate ester is an aryl gallate ester.

Assignees

• Univ Alberta

Inventors

• Jeon Byeonghwa
• Kim Jong-Chul

Classifications

• C07K7/58

  Bacitracins; Related peptides · CPC title

• A61K31/235

  having an aromatic ring attached to a carboxyl group · CPC title

• A61K38/12 Primary

  Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)} · CPC title

• A01N37/40

  having at least one carboxylic group or a thio analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system · CPC title

• A61P31/04

  Antibacterial agents · CPC title